TY - JOUR
T1 - A new role for estrogen receptor a in cell proliferation and cancer
T2 - Activating the anticipatory unfolded protein response
AU - Livezey, Mara
AU - Kim, Ji Eun
AU - Shapiro, David J.
N1 - Publisher Copyright:
© 2018 Livezey, Kim and Shapiro.
PY - 2018/6/15
Y1 - 2018/6/15
N2 - Cells react to a variety of stresses, including accumulation of unfolded or misfolded protein, by activating the endoplasmic reticulum (EnR) stress sensor, the unfolded protein response (UPR). The UPR is highly conserved and plays a key role in the maintenance of protein folding quality control and homeostasis. In contrast to the classical reactive mode of UPR activation, recent studies describe a hormone-activated anticipatory UPR. In this pathway, mitogenic hormones, such as estrogen (E2), epidermal growth factor, and vascular endothelial growth factor rapidly activate the UPR in anticipation of a future need for increased protein folding capacity upon cell proliferation. Here, we focus on this recently unveiled pathway of E2-estrogen receptor a (ERa) action. Notably, rapid activation of the anticipatory UPR pathway is essential for subsequent activation of the E2-ERa regulated transcription program. Moreover, activation of the UPR at diagnosis is a powerful prognostic marker in ERa positive breast cancer. Furthermore, in cells containing ERa mutations that confer estrogen independence and are common in metastatic breast cancer, the UPR is constitutively activated and linked to antiestrogen resistance. Lethal ERa-dependent hyperactivation of the anticipatory UPR represents a promising therapeutic approach exploited by a new class of small molecule ERa biomodulator.
AB - Cells react to a variety of stresses, including accumulation of unfolded or misfolded protein, by activating the endoplasmic reticulum (EnR) stress sensor, the unfolded protein response (UPR). The UPR is highly conserved and plays a key role in the maintenance of protein folding quality control and homeostasis. In contrast to the classical reactive mode of UPR activation, recent studies describe a hormone-activated anticipatory UPR. In this pathway, mitogenic hormones, such as estrogen (E2), epidermal growth factor, and vascular endothelial growth factor rapidly activate the UPR in anticipation of a future need for increased protein folding capacity upon cell proliferation. Here, we focus on this recently unveiled pathway of E2-estrogen receptor a (ERa) action. Notably, rapid activation of the anticipatory UPR pathway is essential for subsequent activation of the E2-ERa regulated transcription program. Moreover, activation of the UPR at diagnosis is a powerful prognostic marker in ERa positive breast cancer. Furthermore, in cells containing ERa mutations that confer estrogen independence and are common in metastatic breast cancer, the UPR is constitutively activated and linked to antiestrogen resistance. Lethal ERa-dependent hyperactivation of the anticipatory UPR represents a promising therapeutic approach exploited by a new class of small molecule ERa biomodulator.
KW - Breast cancer
KW - Calcium
KW - Cancer therapy
KW - Estrogen
KW - Estrogen receptor a
KW - Rapid extranuclear signaling
KW - Unfolded protein response
UR - http://www.scopus.com/inward/record.url?scp=85048605870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048605870&partnerID=8YFLogxK
U2 - 10.3389/fendo.2018.00325
DO - 10.3389/fendo.2018.00325
M3 - Short survey
AN - SCOPUS:85048605870
SN - 1664-2392
VL - 9
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
IS - JUN
M1 - 325
ER -